Zhejiang Cancer Hospital
🇨🇳China
Clinical Trials
248
Active:7
Completed:33
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:18
Phase 2:123
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (210 trials with phase data)• Click on a phase to view related trials
Phase 2
123 (58.6%)Not Applicable
41 (19.5%)Phase 3
19 (9.0%)Phase 1
18 (8.6%)Phase 4
7 (3.3%)Early Phase 1
2 (1.0%)Effect of Small Double-lumen Tube on the Intubation Time of Thoracoscopic Pulmonectomy in Asian Women
Not Applicable
Recruiting
- Conditions
- WomenAsianThoracic Surgery With One-lung Ventilation
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT07097584
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Not Applicable
Not yet recruiting
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Drug: NALIRIRadiation: LCRTDrug: FOLFOX
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT07074353
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
Recruiting
- Conditions
- Gastric Cancer
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 1000000
- Registration Number
- NCT07067983
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .
Phase 2
Not yet recruiting
- Conditions
- Cervical Cancer Stage IVACervical Cancer Metastatic
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT07035808
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: pyrotinib dalpiciclib letrozole
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT07014410
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 49
- Next
News
Fapon Biopharma Enrolls First Patient in Phase I Trial of FP008, Novel Anti-PD-1 Fusion Protein for Solid Tumors
Fapon Biopharma has enrolled the first patient in China for its Phase I clinical trial of FP008, a first-in-class anti-PD-1 × IL-10M fusion protein immunotherapy for advanced solid tumors.